1
|
Nair S, Kumar SR, Paidi VR, Sistla R, Kantheti D, Polimera SR, Thangavel S, Mukherjee AJ, Das M, Bhide RS, Pitts WJ, Murugesan N, Dudhgoankar S, Nagar J, Subramani S, Mazumder D, Carman JA, Holloway DA, Li X, Fereshteh MP, Ruepp S, Palanisamy K, Mariappan TT, Maddi S, Saxena A, Elzinga P, Chimalakonda A, Ruan Q, Ghosh K, Bose S, Sack J, Yan C, Kiefer SE, Xie D, Newitt JA, Saravanakumar SP, Rampulla RA, Barrish JC, Carter PH, Hynes J. Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis. ACS Med Chem Lett 2020; 11:1402-1409. [PMID: 32676146 DOI: 10.1021/acsmedchemlett.0c00082] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Accepted: 06/02/2020] [Indexed: 11/28/2022] Open
Abstract
IRAK4 is an attractive therapeutic target for the treatment of inflammatory conditions. Structure guided optimization of a nicotinamide series of inhibitors has been expanded to explore the IRAK4 front pocket. This has resulted in the identification of compounds such as 12 with improved potency and selectivity. Additionally 12 demonstrated activity in a pharmacokinetics/pharmacodynamics (PK/PD) model. Further optimization efforts led to the identification of the highly kinome selective 21, which demonstrated a robust PD effect and efficacy in a TLR7 driven model of murine psoriasis.
Collapse
Affiliation(s)
- Satheesh Nair
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | | | | | - Ramesh Sistla
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | - Durgarao Kantheti
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | | | | | | | - Mitalee Das
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | - Rajeev S. Bhide
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - William J. Pitts
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Natesan Murugesan
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | | | - Jignesh Nagar
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | - Siva Subramani
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | - Debarati Mazumder
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | - Julie A. Carman
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Deborah A. Holloway
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Xin Li
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Mark P. Fereshteh
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Stefan Ruepp
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | | | | | - Srinivas Maddi
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | - Ajay Saxena
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Paul Elzinga
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Anjaneya Chimalakonda
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Qian Ruan
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Kaushik Ghosh
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | - Sucharita Bose
- Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India
| | - John Sack
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Chunhong Yan
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Susan E. Kiefer
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Dianlin Xie
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - John A. Newitt
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | | | - Richard A. Rampulla
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Joel C. Barrish
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - Percy H. Carter
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| | - John Hynes
- Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States
| |
Collapse
|
2
|
Dudhgaonkar S, Ranade S, Nagar J, Subramani S, Prasad DS, Karunanithi P, Srivastava R, Venkatesh K, Selvam S, Krishnamurthy P, Mariappan TT, Saxena A, Fan L, Stetsko DK, Holloway DA, Li X, Zhu J, Yang WP, Ruepp S, Nair S, Santella J, Duncia J, Hynes J, McIntyre KW, Carman JA. Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity. J Immunol 2017; 198:1308-1319. [PMID: 28003376 PMCID: PMC5253435 DOI: 10.4049/jimmunol.1600583] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Accepted: 11/22/2016] [Indexed: 12/15/2022]
Abstract
The serine/threonine kinase IL-1R-associated kinase (IRAK)4 is a critical regulator of innate immunity. We have identified BMS-986126, a potent, highly selective inhibitor of IRAK4 kinase activity that demonstrates equipotent activity against multiple MyD88-dependent responses both in vitro and in vivo. BMS-986126 failed to inhibit assays downstream of MyD88-independent receptors, including the TNF receptor and TLR3. Very little activity was seen downstream of TLR4, which can also activate an MyD88-independent pathway. In mice, the compound inhibited cytokine production induced by injection of several different TLR agonists, including those for TLR2, TLR7, and TLR9. The compound also significantly suppressed skin inflammation induced by topical administration of the TLR7 agonist imiquimod. BMS-986126 demonstrated robust activity in the MRL/lpr and NZB/NZW models of lupus, inhibiting multiple pathogenic responses. In the MRL/lpr model, robust activity was observed with the combination of suboptimal doses of BMS-986126 and prednisolone, suggesting the potential for steroid sparing activity. BMS-986126 also demonstrated synergy with prednisolone in assays of TLR7- and TLR9-induced IFN target gene expression using human PBMCs. Lastly, BMS-986126 inhibited TLR7- and TLR9-dependent responses using cells derived from lupus patients, suggesting that inhibition of IRAK4 has the potential for therapeutic benefit in treating lupus.
Collapse
Affiliation(s)
| | - Sourabh Ranade
- Biocon Bristol-Myers Squibb Research Center, Bangalore 560099, India
| | - Jignesh Nagar
- Biocon Bristol-Myers Squibb Research Center, Bangalore 560099, India
| | - Siva Subramani
- Biocon Bristol-Myers Squibb Research Center, Bangalore 560099, India
| | - Durga Shiv Prasad
- Biocon Bristol-Myers Squibb Research Center, Bangalore 560099, India
| | | | - Ratika Srivastava
- Biocon Bristol-Myers Squibb Research Center, Bangalore 560099, India
| | - Kamala Venkatesh
- Biocon Bristol-Myers Squibb Research Center, Bangalore 560099, India
| | - Sabariya Selvam
- Biocon Bristol-Myers Squibb Research Center, Bangalore 560099, India
| | | | | | - Ajay Saxena
- Biocon Bristol-Myers Squibb Research Center, Bangalore 560099, India
| | - Li Fan
- Immunology Discovery, Bristol-Myers Squibb, Princeton, NJ 08543
| | - Dawn K Stetsko
- Immunology Discovery, Bristol-Myers Squibb, Princeton, NJ 08543
| | | | - Xin Li
- Lead Evaluation, Bristol-Myers Squibb, Princeton, NJ 08543
| | - Jun Zhu
- Translational Technologies, Bristol-Myers Squibb, Hopewell, NJ 08525
| | - Wen-Pin Yang
- Translational Technologies, Bristol-Myers Squibb, Hopewell, NJ 08525
| | - Stefan Ruepp
- Discovery Toxicology, Bristol-Myers Squibb, Princeton, NJ 08543; and
| | - Satheesh Nair
- Biocon Bristol-Myers Squibb Research Center, Bangalore 560099, India
| | - Joseph Santella
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ 08543
| | - John Duncia
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ 08543
| | - John Hynes
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ 08543
| | - Kim W McIntyre
- Immunology Discovery, Bristol-Myers Squibb, Princeton, NJ 08543
| | - Julie A Carman
- Immunology Discovery, Bristol-Myers Squibb, Princeton, NJ 08543;
| |
Collapse
|
3
|
Menard LC, Habte S, Gonsiorek W, Lee D, Banas D, Holloway DA, Manjarrez-Orduno N, Cunningham M, Stetsko D, Casano F, Kansal S, Davis PM, Carman J, Zhang CK, Abidi F, Furie R, Nadler SG, Suchard SJ. B cells from African American lupus patients exhibit an activated phenotype. JCI Insight 2016; 1:e87310. [PMID: 27699274 DOI: 10.1172/jci.insight.87310] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease driven by both innate and adaptive immune cells. African Americans tend to present with more severe disease at an earlier age compared with patients of European ancestry. In order to better understand the immunological differences between African American and European American patients, we analyzed the frequencies of B cell subsets and the expression of B cell activation markers from a total of 68 SLE patients and 69 normal healthy volunteers. We found that B cells expressing the activation markers CD86, CD80, PD1, and CD40L, as well as CD19+CD27-IgD- double-negative B cells, were enriched in African American patients vs. patients of European ancestry. In addition to increased expression of CD40L, surface levels of CD40 on B cells were lower, suggesting the engagement of the CD40 pathway. In vitro experiments confirmed that CD40L expressed by B cells could lead to CD40 activation and internalization on adjacent B cells. To conclude, these results indicate that, compared with European American patients, African American SLE patients present with a particularly active B cell component, possibly via the activation of the CD40/CD40L pathway. These data may help guide the development of novel therapies.
Collapse
Affiliation(s)
- Laurence C Menard
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Sium Habte
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Waldemar Gonsiorek
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Deborah Lee
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Dana Banas
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Deborah A Holloway
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | | | - Mark Cunningham
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Dawn Stetsko
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Francesca Casano
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Selena Kansal
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Patricia M Davis
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Julie Carman
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Clarence K Zhang
- Immunoscience Translational Bioinformatics, Bristol-Myers Squibb Company, Pennington, New Jersey, USA
| | - Ferva Abidi
- Division of Rheumatology, Northwell Health, Great Neck, New York, USA
| | - Richard Furie
- Division of Rheumatology, Northwell Health, Great Neck, New York, USA
| | - Steven G Nadler
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| | - Suzanne J Suchard
- Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
| |
Collapse
|
4
|
Yang MG, Dhar TGM, Xiao Z, Xiao HY, Duan JJW, Jiang B, Galella MA, Cunningham M, Wang J, Habte S, Shuster D, McIntyre KW, Carman J, Holloway DA, Somerville JE, Nadler SG, Salter-Cid L, Barrish JC, Weinstein DS. Improving the Pharmacokinetic and CYP Inhibition Profiles of Azaxanthene-Based Glucocorticoid Receptor Modulators—Identification of (S)-5-(2-(9-Fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamido)-N-(tetrahydro-2H-pyran-4-yl)-1,3,4-thiadiazole-2-carboxamide (BMS-341). J Med Chem 2015; 58:4278-90. [DOI: 10.1021/acs.jmedchem.5b00257] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Michael G. Yang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - T. G. Murali Dhar
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Zili Xiao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Hai-Yun Xiao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - James J.-W. Duan
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Bin Jiang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Michael A. Galella
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Mark Cunningham
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Jinhong Wang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sium Habte
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David Shuster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Kim W. McIntyre
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Julie Carman
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Deborah A. Holloway
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John E. Somerville
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Steven G. Nadler
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Luisa Salter-Cid
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Joel C. Barrish
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David S. Weinstein
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
5
|
Weinstein DS, Gong H, Doweyko AM, Cunningham M, Habte S, Wang JH, Holloway DA, Burke C, Gao L, Guarino V, Carman J, Somerville JE, Shuster D, Salter-Cid L, Dodd JH, Nadler SG, Barrish JC. Azaxanthene Based Selective Glucocorticoid Receptor Modulators: Design, Synthesis, and Pharmacological Evaluation of (S)-4-(5-(1-((1,3,4-Thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and Its Methylene Homologue (BMS-791826). J Med Chem 2011; 54:7318-33. [DOI: 10.1021/jm200879j] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- David S. Weinstein
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Hua Gong
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Arthur M. Doweyko
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Mark Cunningham
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sium Habte
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Jin Hong Wang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Deborah A. Holloway
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Christine Burke
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Ling Gao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Victor Guarino
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Julie Carman
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John E. Somerville
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David Shuster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Luisa Salter-Cid
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John H. Dodd
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Steven G. Nadler
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Joel C. Barrish
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
6
|
Yang BV, Weinstein DS, Doweyko LM, Gong H, Vaccaro W, Huynh T, Xiao HY, Doweyko AM, McKay L, Holloway DA, Somerville JE, Habte S, Cunningham M, McMahon M, Townsend R, Shuster D, Dodd JH, Nadler SG, Barrish JC. Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated glucocorticoid receptor agonists. J Med Chem 2010; 53:8241-51. [PMID: 21073190 DOI: 10.1021/jm100957a] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A series of 2,2-dimethyl-3,3-diphenyl-propanamides as novel glucocorticoid receptor modulators is reported. SAR exploration led to the identification of 4-hydroxyphenyl propanamide derivatives displaying good agonist activity in GR-mediated transrepression assays and reduced agonist activity in GR-mediated transactivation assays. Compounds 17 and 30 showed anti-inflammatory activity comparable to prednisolone in the rat carrageenan-induced paw edema model, with markedly decreased side effects with regard to increases in blood glucose and expression of hepatic tyrosine aminotransferase. A hypothetical binding mode accounting for the induction of the functional activity by a 4-hydroxyl group is proposed.
Collapse
Affiliation(s)
- Bingwei V Yang
- Bristol-Myers Squibb Company, Research and Development, Princeton, New Jersey 08543-4000, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Yang BV, Vaccaro W, Doweyko AM, Doweyko LM, Huynh T, Tortolani D, Nadler SG, McKay L, Somerville J, Holloway DA, Habte S, Weinstein DS, Barrish JC. Discovery of novel dihydro-9,10-ethano-anthracene carboxamides as glucocorticoid receptor modulators. Bioorg Med Chem Lett 2009; 19:2139-43. [DOI: 10.1016/j.bmcl.2009.03.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2009] [Accepted: 03/03/2009] [Indexed: 11/25/2022]
|
8
|
Monshizadegan DA, Holloway DA, Torrente JM, Yednock T, Fritz L, Sturm RJ. VLA-4-dependent adhesion activities of U937 cells and guinea pig bronchoalveolar lavage leukocytes. Agents Actions 1993; 39 Spec No:C177-9. [PMID: 8273561 DOI: 10.1007/bf01972758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
VLA-4-dependent binding to fibronectin (FN) and to a human vascular cell adhesion molecule (hVCAM-1)-transfected murine cell line was measured using U937 cells and guinea pig (GP) bronchoalveolar lavage (BAL) cells. A species cross-reactive, blocking monoclonal antibody directed against human VLA-4 (TY 21.6) inhibited U937/FN binding by 71 +/- 7%. The presence of TY21.6 inhibited the stimulated binding of U937 cells to hVCAM-1 by 84%. However, TY 21.6 was unable to inhibit the BAL/FN binding. With the addition of TY 21.6, the binding of PMA-stimulated BAL cells to hVCAM-1 was inhibited by 57 +/- 5%. In summary, human and guinea-pig leukocytes express binding activity to both FN and hVCAM-1. A specific VLA-4 blocking monoclonal antibody, TY 21.6, inhibited U937 and BAL cell binding to hVCAM-1, but only inhibited FN binding with U937 cells.
Collapse
|
9
|
Sturm RJ, Holloway DA, Buckley S, Osborne MC, Grimes D, Weichman BM, Rimele TJ. Potential regulatory role of inflammatory cells on local vascular smooth muscle tone. Agents Actions 1989; 27:414-7. [PMID: 2801332 DOI: 10.1007/bf01972838] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
A neutrophil-derived relaxing factor (NDRF) from oyster glycogen (OG)-elicited rat PMN, which causes an endothelium independent relaxation of rat aorta, and which is pharmacologically indistinguishable from endothelium-derived relaxing factor (EDRF) has been described. Experiments were designed to evaluate the presence of NDRF in PMN from rat -whole blood, -carrageenan pleurisy, -OG peritonitis, and guinea pig (GP) -OG peritonitis, as well as in OG-elicited rat macrophages (M phi). Significant vascular relaxing activity was found using rat PMN from OG peritonitis and carrageenan pleurisy, as well as from OG-M phi. Little or no activity was found in rat whole blood PMN or PMN from GP-OG peritonitis. These results suggest that NDRF activity may be expressed upon cellular migration to an inflammatory site in the rat, and may not be present in all species. Also, all inflammatory cells examined were capable of reversing EDRF-dependent relaxations when stimulated to produce superoxide anion suggesting a dual regulatory role for these cells on local vascular tone.
Collapse
Affiliation(s)
- R J Sturm
- Division of Immunopharmacology, Wyeth-Ayerst Research, Princeton, NJ 08543-8000
| | | | | | | | | | | | | |
Collapse
|
10
|
Holloway DA, Heath AG. Ventilatory changes in the golden hamster, Mesocricetus auratus, compared with the laboratory rat, Rattus norvegicus, during hypercapnia and/or hypoxia. Comp Biochem Physiol A Comp Physiol 1984; 77:267-73. [PMID: 6142795 DOI: 10.1016/0300-9629(84)90059-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Tidal volume, respiratory frequency, and minute volume were measured with total body plethysmography. Both hypercapnic (0-7% CO2) and hypoxic (13-21% O2) gas mixtures caused "dose" related hyperventilation in the hamsters. However, there was no synergism between combined stimuli. Rats exhibited greater hyperventilation than the hamsters during hypercapnic + hypoxic and hypercapnic exposures. Hamsters responded more than the rats to hypoxia alone. Greater blood buffering capacity of hamsters is a possible explanation for the species differences in ventilatory sensitivity.
Collapse
|
11
|
Holloway DA. Availability of unit dose packages of drugs: 1975. Hosp Pharm 1975; 10:466, 468-9, 472 passim. [PMID: 10237864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|